Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance * Revised Dial -in Information for the Conference Call* IRVING, Texas --(BUSINESS WIRE)--Aug. 9, 2022-- Biote , a high growth, differentiated medical practice-building business

IRVING, Texas --(BUSINESS WIRE)--Jul. 20, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, will report its financial results for the second quarter ended June 30, 2022 , after market close on

  Innovative physician leader brings over 20 years of experience to Biote’s executive team IRVING, Texas --(BUSINESS WIRE)--Jun. 16, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, today announced

IRVING, Texas --(BUSINESS WIRE)--Jun. 6, 2022-- biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, differentiated medical practice-building business within the hormone optimization space, today announces that Terry Weber , Biote’s Chief Executive Officer, is scheduled to present

Survey reveals 4 out of every 10 women reported that menopause symptoms have interfered with their work performance or productivity at least on a weekly basis IRVING, Texas --(BUSINESS WIRE)--Jun. 6, 2022-- Biote , a leading hormone optimization company, today publicly released findings of a 2022

Business combination with Haymaker Acquisition Corp. III complete biote Corp.’s common stock will trade on the Nasdaq Stock Exchange under ticker symbol “BTMD” IRVING, Texas --(BUSINESS WIRE)--May 26, 2022-- biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE)  — Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the “Business

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE)  — Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, reminds its shareholders to vote in favor of the proposed business combination with BioTE Holdings, LLC (“Biote”) and the

Company accelerates expansion and reiterates 2022 guidance Net sales of $37 million in the quarter, an 18% increase year-over-year from the first quarter of 2021. First quarter procedural revenue grew at 21.2% year-over-year. Adjusted EBITDA of $12 million, a 20% increase year-over-year.1 The

Record net sales of $139.4 million for the full year, a 20% increase year-over-year. Record net sales of $37.5 million in the fourth quarter, a 22% increase period-over-period. EBITDA of $36 million, a 9% increase year-over-year. 1 In December 2021, Biote entered into a business combination